Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Context: The diagnosis of familial hypercholesterolemia (FH) can be made using the Dutch Lipid Clinic Network criteria. This employs the personal and family history of premature coronary artery disease and hypercholesterolemia and the presence of a pathogenic mutation in the low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) genes. Objective: We employed this tool to investigate the prevalence of FH and the associations between FH and coronary artery disease and cholesterol-lowering medication in the Copenhagen General Population Study. Setting: The study was of an unselected, community-based population comprising 69,016 participants. Main Outcome Measures: FH (definite/probable) was defined as a Dutch Lipid Clinic Network score higher than 5. Coronary artery disease was myocardial infarction or angina pectoris. Results: The prevalence of FH was 0.73% (one in 137). Of participants with FH, 20% had an LDLR or APOB mutation. The prevalence of coronary artery disease among FH participants was 33%. Only 48% of subjects with FH admitted to taking cholesterol-lowering medication. The odds ratio for coronary artery disease off cholesterol-lowering medication was 13.2 (10.0–17.4) in definite/probable FH compared with non-FH subjects, after adjusting for age, gender, body mass index, hypertension, metabolic syndrome and diabetes, and smoking. The corresponding adjusted odds ratio for coronary artery disease in FH subjects on cholesterol-lowering medication was 10.3 (7.8–13.8). Conclusion: The prevalence of FH appears to be higher than commonly perceived in a general population of white Danish individuals, with at least half of affected subjects not receiving cholesterol-lowering medication. The very high risk of coronary artery disease irrespective of use of medication reflects the extent of underdiagnosis and undertreatment of FH in the community and primary care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The frequency of HeFH in the population has earlier been estimated at 1/500; however, recent studies from whole populations suggest that the frequency is higher, in some populations as high as 1/137. 297”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [297]
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationJones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Genetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
Self-citationKotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 721
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Research works printed but not linked: 1
- World Health Organization, 1999, Familial hypercholesterolaemia (FH)
Cited by
Items 201–300 of 632
Vickery, A. W., Ryan, J., Pang, J., Garton‐Smith, J., & Watts, G. F. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.09.012 · Cited by 29
Self-citationDetection of familial hypercholesterolemia in patients from a general practice database
Casula, M., Catapano, A. L., Bernardi, L. R., Visconti, M., & Aronica, A. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.07.004 · Cited by 29
Ramakrishnan, V. M., Yang, J., Tien, K. T., McKinley, T. R., Bocard, B. R., Maijub, J. G., Burchell, P., Williams, S. K., Morris, M. E., Hoying, J. B., et al. (2015) · Scientific Reports · doi:10.1038/srep13231 · Cited by 27
Farnier, M., Civeira, F., Descamps, O. S., Kawashiri, M., Grigore, L., & Vohnout, B. (2017) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(17)30022-3 · Cited by 29
Pek, S. L. T., Dissanayake, S., Fong, J. C. W., Lin, M. X., Chan, E. Z. L., Tang, J. I.-S., Lee, C. W., Ong, H. Y., Sum, C. F., Lim, S. C., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.028 · Cited by 29
Familial hypercholesterolemia in very young myocardial infarction
Li, S., Zhang, H., Guo, Y., Wu, N., Zhu, C., Zhao, X., Sun, D., Gao, X., Gao, Y., Zhang, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27248-w · Cited by 27
Jones, L. K., Rahm, A. K., Manickam, K., Butry, L., Lazzeri, A. L., Corcoran, T., Komar, D., Josyula, N. S., Pendergrass, S. A., Sturm, A. C., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002146 · Cited by 28
Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland
Björnsson, E., Þorgeirsson, G., Helgadóttir, A., Þorleifsson, G., Sveinbjörnsson, G., Kristmundsdóttir, S., Jónsson, H., Jónasdóttir, A., Jónasdóttir, Á., Sigurðsson, Á., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315904 · Cited by 32
A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021
Wei, N., Hu, Y., Liu, G., Li, S., Yuan, G., Shou, X., Zhang, X., Shi, J., & Zhai, H. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101151 · Cited by 29
Genetic backgrounds and diagnosis of familial hypercholesterolemia
Rogozik, J. K., Główczyńska, R., & Grabowski, M. (2023) · Clinical Genetics · doi:10.1111/cge.14435 · Cited by 40
Pedersen, S. B., Varbo, A., Langsted, A., & Nordestgaard, B. G. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12713 · Cited by 29
Self-citationKatsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 29
Familial hypercholesterolemia in children and adolescents: A clinical perspective
de Ferranti, S. D. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.04.009 · Cited by 30
A novel approach to screening for familial hypercholesterolemia in a large public venue
Campbell, M., Humanki, J., & Zierhut, H. A. (2016) · Journal of Community Genetics · doi:10.1007/s12687-016-0285-1 · Cited by 27
Efficacy and Safety of Lomitapide in Hypercholesterolemia
Liu, X., Men, P., Wang, Y., Zhai, S., Zhao, Z., & Liu, C. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0214-7 · Cited by 28
Wurtmann, E. J., Steinberger, J., Veach, P. M., Khan, M., & Zierhut, H. A. (2018) · Journal of Genetic Counseling · doi:10.1007/s10897-018-0290-0 · Cited by 28
What Is the Prevalence of Familial Hypercholesterolemia?
Brunham, L. R., & Hegele, R. A. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316862 · Cited by 25
Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk
Noto, D., Cefalu, A. B., & Averna, M. R. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0414-4 · Cited by 28
Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey
Schofield, J. D., Kwok, S., France, M. W., Capps, N. E., Eatough, R., Yadav, R., Ray, K. K., & Soran, H. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.009 · Cited by 25
Chua, Y.-A., Razman, A. Z., Ramli, A. S., Kasim, N. A. M., & Nawawi, H. M. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.57026 · Cited by 32
Medeiros, A. M., Alves, A. C., Aguiar, P. M. V., & Bourbon, M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.p043182 · Cited by 31
Page, M. M., Stefanutti, C., Sniderman, A. D., & Watts, G. F. (2015) · Clinical Science · doi:10.1042/cs20140755 · Cited by 26
Self-citationIdentifying familial hypercholesterolemia in acute coronary syndrome
Gencer, B., & Nanchen, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000311 · Cited by 30
Kolovou, G. D., Kolovou, V., Papadopoulou, A., & Watts, G. F. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34777 · Cited by 25
Self-citationFutema, M., Cooper, J. A., Charakida, M., Boustred, C. R., Sattar, N. A., Deanfield, J. E., Lawlor, D. A., Timpson, N. J., Humphries, S. E., & Hingorani, A. D. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.007 · Cited by 29
Vrablík, M., Rašlová, K., Vohnout, B., Blaha, V., Satny, M., Kyselák, O., Vaclová, M., Urbánek, R., Mašková, J., Soška, V., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.008 · Cited by 28
Turunen, T. A. K., Kurkipuro, J., Heikura, T., Vuorio, T., Hytönen, E., Izsvák, Z., & Ylä‐Herttuala, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.221 · Cited by 24
Children with hypercholesterolemia of unknown cause: Value of genetic risk scores
Sjouke, B., Tanck, M. W. T., Fouchier, S. W., Defesche, J. C., Hutten, B. A., Wiegman, A., Kastelein, J. J. P., & Hovingh, G. K. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.02.017 · Cited by 26
Carroll, C., Tappenden, P., Rafia, R., Hamilton, J. A., Chambers, D., Clowes, M., Durrington, P. N., Qureshi, N., & Wierzbicki, A. S. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0492-6 · Cited by 24
Actionable Exomic Secondary Findings in 280 Lebanese Participants
Jalkh, N., Mehawej, C., & Chouery, É. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00208 · Cited by 24
Langslet, G., Bogsrud, M. P., Halvorsen, I., Fjeldstad, H. E., Retterstøl, K., Veierød, M. B., & Ose, L. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.08.008 · Cited by 27
Familial Hypercholesterolemia: Advances in Recognition and Therapy
Cartier, J. L., & Goldberg, A. C. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.006 · Cited by 29
Hartgers, M. L., Besseling, J., Stroes, E. S. G., Wittekoek, J., Rutten, J. H. W., Graaf, J. D., Visseren, F. L. J., Imholz, B. P. M., van Lennep, J. E. R., Huijgen, R., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.002 · Cited by 24
Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries
Alhababi, D., & Zayed, H. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.10.022 · Cited by 25
Helk, O., & Widhalm, K. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2019.09.009 · Cited by 27
Monogenic, polygenic, and oligogenic familial hypercholesterolemia
Tada, H., Nohara, A., & Kawashiri, M. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000609 · Cited by 30
Jones, L. K., Campbell‐Salome, G., Walters, N., Brangan, A., Morgan, K., Tricou, E. P., Lindsey‐Mills, Z., McGowan, M. P., Gidding, S. S., Johns, A. M., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101198 · Cited by 27
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 67
Cascade Screening in Familial Hypercholesterolemia: Advancing Forward
Santos, R. D., Frauches, T. S., & Chacra, A. P. M. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.31237 · Cited by 25
Nikkilä, K., Åberg, F. O., & Isoniemi, H. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12961 · Cited by 23
Wang, H., Xu, S., Sun, L., Pan, X., Yang, S., & Wang, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092703 · Cited by 25
Fahed, A. C., Khalaf, R. I., Salloum, R. H., Andary, R. R., Safa, R., El‐Rassy, I., Moubarak, E. M., Azar, S. T., Bitar, F. F., & Nemer, G. M. (2016) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.203 · Cited by 31
Séguro, F., Rabès, J., Taraszkiewicz, D., Ruidavets, J., Bongard, V., & Ferrières, J. (2018) · Clinical Cardiology · doi:10.1002/clc.22881 · Cited by 26
Blom, D. J., Almahmeed, W. A., Al‐Rasadi, K., Azuri, J., Daclin, V., Kayıkçıoğlu, M., Mercier, F., Ruiz, Á. J., & Santos, R. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.004 · Cited by 26
Patel, P., Hu, Y., Kolinovsky, A. N., Geng, Z., Ruhl, J. A., Krishnamurthy, S. B., deRichemond, C., Khan, A., Kirchner, H. L., Metpally, R. P. R., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011822 · Cited by 24
Wang, Y., Li, Y., Liu, X., Tu, R., Zhang, H., Qian, X., Jiang, J., Qiao, D., Liu, X., Luo, Z., et al. (2019) · BMC Public Health · doi:10.1186/s12889-019-7212-4 · Cited by 24
Olmastroni, E., Gazzotti, M., Arca, M., Averna, M., Pirillo, A., Catapano, A. L., Casula, M., Bertolini, S., Calandra, S., Tarugi, P., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023668 · Cited by 24
Radoviča-Spalviņa, I., Latkovskis, G., Silamiķelis, I., Frīdmanis, D., Elbere, I., Ventiņš, K., Ozola, G., Ērglis, A., & Kloviņš, J. (2015) · BMC Medical Genetics · doi:10.1186/s12881-015-0230-x · Cited by 28
Alharbi, K. K., Kashour, T. S., Al-Hussaini, W., Nbaheen, M. S., Hasanato, R. M. W., Mohamed, S., Tamimi, W., & Khan, I. A. (2015) · Acta Biochimica Polonica · doi:10.18388/abp.2015_1015 · Cited by 22
Béliard, S., Millier, A., Carreau, V., Carrié, A., Moulin, P., Fredenrich, A., Farnier, M., Luc, G., Rosenbaum, D. H., Toumi, M., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.007 · Cited by 24
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 31
Azraii, A. B., Ramli, A. S., Ismail, Z., Abdul-Razak, S., Kasim, N. A. M., Ali, N., Watts, G. F., & Nawawi, H. M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.018 · Cited by 22
Self-citationImpact of the Integrated Guidance on the Care of Familial Hypercholesterolaemia
Arai, H., Ding, Y.-A., & Yamashita, S. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.23754 · Cited by 22
Schmidt, N., Schmidt, B., Dressel, A., Gergei, I., Klotsche, J., Pieper, L., Scharnagl, H., Kleber, M. E., März, W., Lehnert, H., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.019 · Cited by 22
Kjærgaard, K. A., Christiansen, M. K., Schmidt, M., Olsen, M. S., & Jensen, H. K. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005435 · Cited by 25
Bouhairie, V. E., & Goldberg, A. C. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.001 · Cited by 22
Saadatagah, S., Alhalabi, L., Farwati, M., Zordok, M., Bhat, A., Smith, C. Y., Wood‐Wentz, C. M., Bailey, K. R., & Kullo, I. J. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100393 · Cited by 21
Brænne, I., Reiz, B., Medack, A., Kleinecke, M., Fischer, M., Tuna, S., Hengstenberg, C., Deloukas, P., Erdmann, J., & Schunkert, H. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-108 · Cited by 22
The Genetic Spectrum of Familial Hypercholesterolemia (FH) in the Iranian Population
Fairoozy, R. H., Futema, M., Vakili, R., Abbaszadegan, M. R., Hosseini, S., Aminzadeh, M., Zaeri, H., Mobini, M., Humphries, S. E., & Sahebkar, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17181-9 · Cited by 22
Hedegaard, B. S., Nordestgaard, B. G., Kanstrup, H., Thomsen, K. K., Bech, J. W., Bang, L. E., Henriksen, F. L., Andersen, L. J., Gohr, T., Larsen, L., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad625 · Cited by 23
Self-citationBaum, S. J., Sijbrands, E. J. G., Mata, P., & Watts, G. F. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.005 · Cited by 21
Self-citationDanchin, N., Farnier, M., Zeller, M., Puymirat, É., Cottin, Y., Belle, L., Lemesle, G., Cayla, G., Ohlmann, P., Jacquemin, L., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.03.008 · Cited by 21
Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia
Ferrari, F., Martins, V. M., Rocha, V. Z., & Santos, R. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1832991 · Cited by 23
Bellows, B. K., Khera, A. V., Zhang, Y., Ruiz‐Negrón, N., Stoddard, H. M., Wong, J. B., Kazi, D. S., de Ferranti, S. D., & Moran, A. E. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025192 · Cited by 26
Albuquerque, J., Medeiros, A. M., Alves, A. C., Bourbon, M., & Antunes, M. C. D. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269713 · Cited by 23
Rangarajan, N. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/18798.7893 · Cited by 20
Wang, X., Cai, G., Wang, Y., Liu, R., Xi, Z., Li, G., Wen, W., Wu, Y., Wang, C., Ji, Q., et al. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1074-8 · Cited by 21
Sawhney, J. P. S., & Madan, K. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2023.12.002 · Cited by 30
Paragh, G., Harangi, M., Karányi, Z., Daróczy, B., Németh, Á., & Fülöp, P. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.039 · Cited by 24
Ajufo, E. C., deGoma, E. M., Raper, A. C., Yu, K. D., Cuchel, M., & Rader, D. J. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01192-z · Cited by 19
Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions
Jahn, B., Santamaria, J., Dieplinger, H., Binder, C. J., Ebenbichler, C. F., Scholl‐Bürgi, S., Conrads‐Frank, A., Rochau, U., Kühne, F., Stojkov, I., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1011 · Cited by 21
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
Self-citationMeng, R., Wei, Q., Zhou, J., Zhang, B., Li, C., & Shen, M. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.11.001 · Cited by 19
Chronic Inflammation and Atherosclerosis
Nilsson, J. Å., Gonçalves, I., & Edsfeldt, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801387-8.00016-8 · Cited by 20
Moriarty, P. M., Parhofer, K. G., Babirak, S. P., deGoma, E. M., Duell, P. B., Hohenstein, B., Ramlow, W., Simha, V., Steinhagen‐Thiessen, E., Thompson, P. D., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.02.003 · Cited by 19
Auckle, R., Su, B., Li, H., Xu, S., Xie, M., Song, Y., Quddus, M. A., Xu, Y., Liu, B., & Che, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186815 · Cited by 23
Rizos, C. V., Athyros, V. G., Bilianou, E., Chrousos, G. P., Garoufi, A., Kolovou, G. D., Kotsis, V., Rallidis, L. S., Skalidis, E., Skoumas, I., et al. (2017) · HORMONES · doi:10.1007/bf03401525 · Cited by 20
PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives
Fitzgerald, G., & Kiernan, T. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1497975 · Cited by 21
Role of non‐coding variants in cardiovascular disease
Heshmatzad, K., Naderi, N., Maleki, M., Abbasi, S., Ghasemi, S., Ashrafi, N., Fazelifar, A. F., Mahdavi, M., & Kalayinia, S. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17762 · Cited by 18
A Web-Based Registry for Familial Hypercholesterolaemia
Napier, K. R., Pang, J., Lamont, L., Walker, C. E., Dawkins, H. J. S., Hunter, A. A., BOCKXMEER, F. M. V., Watts, G. F., & Bellgard, M. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.10.019 · Cited by 18
Self-citationPhenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?
Santos, R. D. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000391 · Cited by 20
Improving the detection of familial hypercholesterolaemia
Lan, N. S. R., Martin, A. C., Brett, T., Watts, G. F., & Bell, D. A. (2018) · Pathology · doi:10.1016/j.pathol.2018.10.015 · Cited by 22
Self-citationInflammatory Biomarkers for Cardiovascular Risk Stratification in Familial Hypercholesterolemia
Bahrami, A., Liberale, L., Reiner, Ž., Carbone, F., Montecucco, F., & Sahebkar, A. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_26 · Cited by 20
Genetic Diagnosis of Familial Hypercholesterolemia in Asia
Huang, C., & Charng, M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00833 · Cited by 20
Dušková, L., Nohelová, L., Loja, T., Fialová, J., Zapletalová, P., Réblová, K., Tichý, L., Freiberger, T., & Fajkusová, L. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00691 · Cited by 17
Tarugi, P., Bertolini, S., Calandra, S., Arca, M., Angelico, F., Casula, M., Cefalu, A. B., D’Erasmo, L., Fortunato, G., Filardi, P. P., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.002 · Cited by 20
Recommendations for the Management of Patients with Familial Hypercholesterolemia
Feldman, D. I., Blaha, M. J., Santos, R. D., Jones, S. R., Blumenthal, R. S., Toth, P. P., Sperling, L. S., & Martin, S. S. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0473-6 · Cited by 18
Pediatric Statin Administration: Navigating a Frontier with Limited Data
Wagner, J. B., & Abdel‐Rahman, S. M. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.5.380 · Cited by 22
Frequency of Achilles Tendon Xanthoma in Patients with Acute Coronary Syndrome
Harada, T., Tanimura‐Inagaki, K., Nagao, M., Sato, Y., Sudo, M., Okajima, F., Sugihara, H., & Oikawa, S. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.37770 · Cited by 17
Alharbi, K. K., Kashour, T. S., Al-Hussaini, W., Al-Nbaheen, M. S., Mohamed, S., Hasanato, R. M. W., Tamimi, W., Al-Naami, M. Y., & Khan, I. A. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-177 · Cited by 17
Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review
Neef, D., Berthold, H. K., & Gouni‐Berthold, I. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1162095 · Cited by 18
Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia
Pears, R., Griffin, M., Futema, M., & Humphries, S. E. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000173 · Cited by 18
Hovingh, G. K., & Kastelein, J. J. P. (2016) · Circulation · doi:10.1161/circulationaha.116.023942 · Cited by 20
Novel treatment options for the management of heterozygous familial hypercholesterolemia
Polychronopoulos, G., & Τζιόμαλος, Κ. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1378096 · Cited by 16
Ramos, R., Masana, L., Comas‐Cufí, M., García-Gil, M., Martí‐Lluch, R., Ponjoan, A., Plana, N., Alves‐Cabratosa, L., Marrugat, J., Elosúa, R., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.10.016 · Cited by 20
Knowles, J. W., Stone, N. J., & Ballantyne, C. M. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.04.062 · Cited by 16
Challenges in the care of familial hypercholesterolemia: a community care perspective
Brett, T., Watts, G. F., Arnold-Reed, D. E., Bell, D. A., Garton‐Smith, J., Vickery, A. W., Ryan, J. D. M., & Pang, J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1082907 · Cited by 17
Self-citationLomitapide: a novel drug for homozygous familial hypercholesterolemia
Panno, M. D., Cefalu, A. B., & Averna, M. R. (2014) · Clinical Lipidology · doi:10.2217/clp.13.74 · Cited by 17
Mulder, J., Galema-Boers, A., de Jong-Verweij, L. M., Hazelzet, J., & van Lennep, J. R. R. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.11.030 · Cited by 13
Pasta, A., Cremonini, A. L., Formisano, E., Fresa, R., Bertolini, S., & Pisciotta, L. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.006 · Cited by 16
Metadata
- Authors
- Benn, M., Watts, G. F., Tybjaerg-Hansen, A., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- The University of Western Australia (AU)
- The Copenhagen General Population Study (M.B., A.T.-H., B.G.N.), Herlev Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark
- Corresponding author
- Nordestgaard, Børge G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-11-01
- Volume
- 97
- Issue
- 11
- Pages
- 3956-3964
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1993634977
- Cited by
- 632
- References
- 38
- Citations by year
- 2026: 28 · 2025: 23 · 2024: 28 · 2023: 37 · 2022: 42 · 2021: 36 · 2020: 44 · 2019: 48 · 2018: 61 · 2017: 80 · 2016: 92 · 2015: 53 · 2014: 42 · 2013: 15 · 2012: 1
- FWCI
- 36.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Sundhed og Sygdom, Det Frie Forskningsråd
- Regeneron Pharmaceuticals
- Gentofte Hospital
- Herlev Hospital
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- familial hypercholesterolemia, prevalence, coronary artery disease, cholesterol-lowering drugs, LDLR mutations, APOB mutations, Dutch Lipid Clinic Network criteria, underdiagnosis, undertreatment, myocardial infarction, angina pectoris, Copenhagen General Population Study
- MeSH terms
- Aged, Anticholesteremic Agents, Coronary Artery Disease, Denmark, Female, Genotype, Humans, Hyperlipoproteinemia Type II, Lipids, Lipoproteins, Male, Middle Aged, Risk, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.